Scope and purpose
Teloryx is an independent educational publisher. It is not a healthcare provider, pharmacy, laboratory, manufacturer, or peptide vendor. We do not diagnose, prescribe, recommend a dose, verify a commercial vial, or determine whether any substance is appropriate for a particular person.
Our purpose is to separate what regulators and human studies actually establish from preclinical findings, indirect evidence, and unsupported online claims. Concentration arithmetic is kept separate from evidence of identity, sterility, safety, efficacy, route, and clinical appropriateness.
Evidence hierarchy
Every completed English-language review receives one of four grades. The grade applies only to the compound, formulation, indication, population, route, and outcome described on that page; it is not a general safety score.
- Grade A — established human evidence: current regulatory approval for a defined product and indication, or comparably strong, consistent human evidence. Approval never transfers automatically to a research vial, compounded copy, different salt, blend, route, dose, or manufacturer.
- Grade B — meaningful investigational human evidence: controlled human trials provide a credible efficacy or biological signal, but the use remains investigational, unapproved, incomplete, or uncertain.
- Grade C — limited, mixed, negative, or indirect human evidence: human exposure exists, but the studies are small, old, methodologically limited, inconsistent, negative, formulation-ambiguous, or not sufficient for a reliable clinical conclusion.
- Grade D — preclinical or indirect evidence only: claims rest mainly on animal, cell, mechanistic, related-compound, or otherwise non-clinical evidence. Human efficacy and an established human dose have not been demonstrated.
Review pending is not a grade. It means the page has not yet passed the source-by-source audit and its prose should be treated as unverified background.
How sources are selected
We prioritize current prescribing information and regulator assessments, official trial registries, peer-reviewed primary human studies, systematic reviews, and primary preclinical papers. A trial registration proves that a study was registered; it does not prove a favorable result. A chemical database identifier, patent, orphan-drug designation, compounding nomination, or foreign marketing claim does not prove approval, efficacy, or safety.
Vendor pages, clinics, social media, forums, unsourced charts, search-result snippets, and marketing copy are not accepted as evidence for a medical claim. Secondary reviews may provide context, but material conclusions are checked against the underlying primary or official source whenever it is available.
Claim review and product specificity
For a completed review, citation numbers in the article must map to the linked source list. We check study population, comparator, route, formulation, dose context, endpoint, duration, sample size, major limitations, adverse-event reporting, regulatory status, and the date through which the search was performed.
Evidence is not transferred between different molecules merely because their names or mechanisms are similar. It is also not transferred automatically between free base and salt forms, oral and injectable routes, approved and compounded products, single ingredients and blends, or endogenous biology and an administered commercial product.
Dosage and procedural safeguards
Teloryx does not derive a personal regimen from animal studies, vendor instructions, anecdotal practice, or an unrelated approved product. Unverified protocol tables and procedural guides are withheld while the audit is underway. The calculator accepts source-supplied values and performs concentration conversion only; a mathematically correct output does not establish that the inputs or resulting administration are medically valid.
Authorship and clinical review
Pages are published under the Teloryx editorial identity. Teloryx does not claim that a physician, pharmacist, scientist, or other credentialed reviewer approved a page unless that person is named on the page with their relevant qualification, role, and review date. A generic editorial label is not a substitute for clinical review.
Updates, corrections, and conflicts
Each completed evidence review displays its review date and linked sources. Regulatory status and scientific evidence can change, so readers should check the date and the current source record. Substantive corrections are made in the article and its evidence manifest; pages may return to pending status if a material claim can no longer be verified.
To report an error, use the contact form and include the page, disputed statement, and supporting source. Teloryx does not sell peptides and does not accept vendor control over coverage, grades, conclusions, or corrections. The site currently states no peptide-sales affiliate relationship; any future material sponsorship or conflict would require clear page-level disclosure.